The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
Christopher D GockeDouglas E GladstonePublished in: British journal of haematology (2017)